Interaction of decamethonium with hexamethonium or vecuronium in the rat: an isobolographic analysis.
We used isobolographic analysis to investigate the interaction of decamethonium with either hexamethonium or vecuronium in the rat phrenic nerve hemidiaphragm preparation. EC50 values of decamethonium, hexamethonium, and vecuronium were (mean +/- SEM) 47.36 +/- 9.58 microM, 4.27 +/- 0.53 mM, and 5.19 +/- 1.17 microM, respectively. Combinations of drugs in concentrations corresponding to the 1:2, 1:1, and 2:1 ratios of their EC50 values were used to determine three points of each isobole. Decamethonium and hexamethonium showed antagonism: significant deviations from the line of additivity were found at EC50 ratios of 2:1 and 1:1 (P < 0.01 and P < 0.05, respectively) indicating that hexamethonium is a potent antagonist of decamethonium. For decamethonium and vecuronium none of the three points on the isobole was significantly different from the corresponding point on the line of additivity. Hexamethonium is known to be a weak antagonist at the postsynaptic nicotinic acetylcholine receptor but a potent antagonist at the presynaptic nicotinic receptor. Vecuronium is a more potent antagonist at the postsynaptic nicotinic receptor but a much weaker antagonist at the presynaptic site. It was postulated that in the rat the primary site of action of decamethonium is at the presynaptic nerve terminal. Our findings suggest that presynaptic rather than postsynaptic potency of a nondepolarizing drug determines ability to antagonize the effect of a depolarizing drug in the rat.
Redai
I
I
Magill Department of Anaesthetics, Chelsea and Westminster Hospital, Charing Cross and Westminster Medical School, London, United Kingdom.
Richards
K M
KM
England
A J
AJ
Feldman
S A
SA
D000818:Animals; D003650:Decamethonium Compounds / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D018738:Hexamethonium / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D009467:Neuromuscular Depolarizing Agents / Q000494:pharmacology*; D010791:Phrenic Nerve / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D014673:Vecuronium Bromide / Q000494:pharmacology*
D003650:Decamethonium Compounds; D009467:Neuromuscular Depolarizing Agents; D018738:Hexamethonium; D014673:Vecuronium Bromide; C033019:decamethonium